title: Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.
abstract: This portion of the NCCN Guidelines for Colon Cancer focuses on the use of systemic therapy in metastatic disease. Considerations for treatment selection among 32 different monotherapies and combination regimens in up to 7 lines of therapy have included treatment history, extent of disease, goals of treatment, the efficacy and toxicity profiles of the regimens,KRAS/NRASmutational status, and patient comorbidities and preferences. Location of the primary tumor, theBRAFmutation status, and tumor microsatellite stability should also be considered in treatment decisions.
authors.forename: Al B
authors.initials: AB
authors.lastname: Benson
authors.forename: Alan P
authors.initials: AP
authors.lastname: Venook
authors.forename: Lynette
authors.initials: L
authors.lastname: Cederquist
authors.forename: Emily
authors.initials: E
authors.lastname: Chan
authors.forename: Yi-Jen
authors.initials: YJ
authors.lastname: Chen
authors.forename: Harry S
authors.initials: HS
authors.lastname: Cooper
authors.forename: Dustin
authors.initials: D
authors.lastname: Deming
authors.forename: Paul F
authors.initials: PF
authors.lastname: Engstrom
authors.forename: Peter C
authors.initials: PC
authors.lastname: Enzinger
authors.forename: Alessandro
authors.initials: A
authors.lastname: Fichera
authors.forename: Jean L
authors.initials: JL
authors.lastname: Grem
authors.forename: Axel
authors.initials: A
authors.lastname: Grothey
authors.forename: Howard S
authors.initials: HS
authors.lastname: Hochster
authors.forename: Sarah
authors.initials: S
authors.lastname: Hoffe
authors.forename: Steven
authors.initials: S
authors.lastname: Hunt
authors.forename: Ahmed
authors.initials: A
authors.lastname: Kamel
authors.forename: Natalie
authors.initials: N
authors.lastname: Kirilcuk
authors.forename: Smitha
authors.initials: S
authors.lastname: Krishnamurthi
authors.forename: Wells A
authors.initials: WA
authors.lastname: Messersmith
authors.forename: Mary F
authors.initials: MF
authors.lastname: Mulcahy
authors.forename: James D
authors.initials: JD
authors.lastname: Murphy
authors.forename: Steven
authors.initials: S
authors.lastname: Nurkin
authors.forename: Leonard
authors.initials: L
authors.lastname: Saltz
authors.forename: Sunil
authors.initials: S
authors.lastname: Sharma
authors.forename: David
authors.initials: D
authors.lastname: Shibata
authors.forename: John M
authors.initials: JM
authors.lastname: Skibber
authors.forename: Constantinos T
authors.initials: CT
authors.lastname: Sofocleous
authors.forename: Elena M
authors.initials: EM
authors.lastname: Stoffel
authors.forename: Eden
authors.initials: E
authors.lastname: Stotsky-Himelfarb
authors.forename: Christopher G
authors.initials: CG
authors.lastname: Willett
authors.forename: Christina S
authors.initials: CS
authors.lastname: Wu
authors.forename: Kristina M
authors.initials: KM
authors.lastname: Gregory
authors.forename: Deborah
authors.initials: D
authors.lastname: Freedman-Cass
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000175:diagnosis* / Q000209:etiology / Q000401:mortality / Q000628:therapy*; D003131:Combined Modality Therapy; D019468:Disease Management; D018450:Disease Progression; D006801:Humans; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D019233:Retreatment; D013997:Time Factors; D016896:Treatment Outcome